EYLEA represents an important new therapy in the treatment of AMD,” said Phil Hagerman, president and CEO of Diplomat. “AMD is becoming more prevalent in Americans over the age of 60, and Diplomat looks forward to helping patients with this disease.
Flint, Michigan (PRWEB) January 09, 2012
Diplomat Specialty Pharmacy, the nation’s largest independent specialty pharmacy in the nation, announced today it has received limited distribution rights from Regeneron for its new drug EYLEA™ (aflibercept) Injection.
On November 18, 2011, EYLEA (aflibercept) Injection was approved by the Food and Drug Administration and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Macular degeneration is diagnosed as either dry (non-vascular) or wet (vascular) and is a leading cause of blindness in older adults. The wet form usually leads to more serious vision loss.
“EYLEA represents an important new therapy in the treatment of AMD,” said Phil Hagerman, president and CEO of Diplomat. “AMD is becoming more and more prevalent in Americans 60 years of age and older; Diplomat looks forward to providing services to help treat this growing population of patients to slow the progression of this disease.”
About Diplomat Specialty Pharmacy
Michigan-based Diplomat Specialty Pharmacy, founded in 1975, serves patients nationwide as the country’s largest privately held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Diplomat’s business model creates unique partnerships around both distribution and services with industry stakeholders with Group Purchasing Organizations, Hospital systems, retail chains and managed markets, always focused on improving adherence and the patient experience. Learn more about Keeping Patients Healthier…Longer® at http://www.diplomatpharmacy.com